The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Lisocabtagene maraleucel in R/R MZL: findings from the Phase II TRANSCEND study
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, reports findings from the Phase II TRANSCEND study (NCT04245839), which is evaluating lisocabtagene maraleucel in relapsed/refractory (R/R) marginal zone lymphoma (MZL). Dr Kamdar reports encouraging safety and efficacy outcomes. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Marginal zone lymphoma has really been a subtype of lymphoma with an unmet need. A lot of trials, unfortunately, exclude marginal zone lymphoma. So kudos to the investigators and the sponsor for doing a dedicated marginal zone lymphoma study, especially in the relapse setting, investigating CD19 CAR T-cell therapy with lisocabtagene maraleucel. So, the TRANSCEND study investigated patients who had relapsed/refractory marginal zone lymphoma after two or more prior lines of treatment, including chemoimmunotherapy, and they were administered lisocabtagene maraleucel...
Marginal zone lymphoma has really been a subtype of lymphoma with an unmet need. A lot of trials, unfortunately, exclude marginal zone lymphoma. So kudos to the investigators and the sponsor for doing a dedicated marginal zone lymphoma study, especially in the relapse setting, investigating CD19 CAR T-cell therapy with lisocabtagene maraleucel. So, the TRANSCEND study investigated patients who had relapsed/refractory marginal zone lymphoma after two or more prior lines of treatment, including chemoimmunotherapy, and they were administered lisocabtagene maraleucel. The net is that the overall response rate was exceptional, over 90% with a CR rate of 65%. And these are holding up. They are durable responses. The safety is highly manageable, especially with regards to cytokine release syndrome, as well as very minimal neurotoxicity. This is a step forward in the direction of improving outcomes for our patients with relapsed refractory marginal zone lymphoma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
